by Kazeem Olalekan
The following are some of the latest important updates from the newly April 2014 release of the BNF and BNFc:
“There is no evidence to show that any oral preparation of mesalazine is more effective than another, however delivery characteristics of oral mesalazine preparations may vary. If it is necessary to switch a patient to a different brand of mesalasine, the patient should be advised to report any changes in symptoms”
Following from previous update
on restriction of Metoclopramide in children, the recommended dose is:
100 – 150 microgram/kg, repeated up to 3 times a day
IV doses should be administered as a slow bolus over at least 3 minutes.
There is an increased risk of venous thromboembolic disease in users of combined hormonal contraceptives, particularly during the first year and possibly after restarting combined hormonal contraceptives following break of four weeks or more. In all cases the risk of venous thromboembolism increases with age & other risk factors, such as obesity, diabetes etc.
Risk is considerably smaller than that associated with pregnancy….but:
There are others: Do look at the BNF